SIMFIBRATE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H26Cl2O6
Molecular Weight	469.355
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCCOC(=O)C(C)(C)OC2=CC=C(Cl)C=C2

InChI

InChIKey=JLRNKCZRCMIVKA-UHFFFAOYSA-N

InChI=1S/C23H26Cl2O6/c1-22(2,30-18-10-6-16(24)7-11-18)20(26)28-14-5-15-29-21(27)23(3,4)31-19-12-8-17(25)9-13-19/h6-13H,5,14-15H2,1-4H3

HIDE SMILES / InChI

Molecular Formula	C23H26Cl2O6
Molecular Weight	469.355
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.genome.jp/dbget-bin/www_bget?D01212
Curator's Comment: Description was created based on several sources, including http://link.springer.com.sci-hub.cc/article/10.1007/BF03286654

Simfibrate, a derivative of clofibrate, is a hypolipidemic drug, that lowers serum chlolesterol and triglycerids. Under the brand name Cholesolvin it is indicated for hyperlipidaemia associated with arteriosclerosis, cerebral atherosclerosis, coronary arteriosclerosis, hypertension, diabetes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Triglyceride Biosynthesis 1 Target ID: WP266 Sources: http://www.genome.jp/dbget-bin/www_bget?D01212	Inhibitor 8504
Platelet activation, signaling and aggregation 1 Target ID: WP3481 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6417824	Inhibitor 8504
Cholesterol Biosynthesis 2 Target ID: WP197 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6417824	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperlipidemia 82 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6417824	Primary		Approved 8583	Cholesolvin Approved Use Indications: hyperlipidaemia associated with arteriosclerosis, cerebral atherosclerosis, coronary arteriosclerosis, hypertension, diabetes.

Doses

Dose	Population	Adverse events
1.5 g 1 times / day multiple, oral Studied dose Dose: 1.5 g, 1 times / day Route: oral Route: multiple Dose: 1.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6417824/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6417824/	Sources: https://pubmed.ncbi.nlm.nih.gov/6417824/

PubMed

Title	Date	PubMed
Response to: Laparoscopic cholecystectomy is safe and effective for the treatment of biliary dyskinesia in the pediatric population.	2010-12	21265362

Patents

Sample Use Guides

In Vivo Use Guide

1.5 g/day P.O

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:24:47 GMT 2025` Edited by `admin` on `Mon Mar 31 18:24:47 GMT 2025`
Record UNII	L2R75RQX26
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SIMFIBRATE

Official Name

English

CHOLESOLVIN

Preferred Name

English

SIMFIBRATE [MI]

Common Name

English

CLY-503

Code

English

Simfibrate [WHO-DD]

Common Name

English

simfibrate [INN]

Common Name

English

SIMFIBRATE [JAN]

Common Name

English

SIMFIBRATE [MART.]

Common Name

English

Classification Tree Code System Code

WHO-ATC

C10AB06